References
- DasSCrockettJCOsteoporosis – a current view of pharmacological prevention and treatmentDrug Des Devel Ther20137435448
- MeltonLJ3rdKhoslaSMalkasianGDAchenbachSJObergALRiggsBLFracture risk after bilateral oophorectomy in elderly womenJ Bone Miner Res200318590090512733730
- Committee of Japanese Guidelines for the Prevention and Treatment of OsteoporosisJapanese Guidelines for the Prevention and Treatment of OsteoporosisTokyoLife Science2011
- KanisJAJohnellOBlackDMEffect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trialBone200333329330013678769
- IikuniNHamayaENihojimaSSafety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillanceJ Bone Miner Metab201230667468222752125
- DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
- TanishimaSMorioYA review of minodronic acid hydrate for the treatment of osteoporosisClin Interv Aging2013818518923440003
- MatsumotoTHaginoHShirakiMEffect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind studyOsteoporos Int20092081429143719101754
- EttingerBBlackDMMitlakBHReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA1999282763764510517716
- DelmasPDEnsrudKEAdachiJDEfficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialJ Clin Endocrinol Metab20028783609361712161484
- QuYWongMThiebaudDStockJLThe effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trialCurr Med Res Opin200521121955195916368046
- HaginoHShirakiMFukunagaMThree years of treatment with minodronate in patients with postmenopausal osteoporosisJ Bone Miner Metab201230443944622134624
- CosmanFWermersRARecknorCEffects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agentJ Clin Endocrinol Metab200994103772378019584192
- CosmanFKeavenyTMKopperdahlDHip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifeneJ Bone Miner Res20132861328133623281041
- EbinaKHashimotoJKashiiMThe effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosisJ Bone Miner Metab2017351919826762133
- JakobFOertelHLangdahlBEffects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational StudyEur J Endocrinol20121661879722048967
- EikenPVestergaardPTreatment of osteoporosis after alendronate or risedronateOsteoporos Int2016271112
- SakaiAIkedaSOkimotoNClinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI studyOsteoporos Int20142592245225324899103
- EbinaKNoguchiTHiraoMEffects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective studyOsteoporos Int201627135135926475289